Auxilium (AUXL) Gets U.S. Patent for Testosterone Gel Testim 1%

Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) and FCB I LLC announced that the United States Patent and Trademark Office ("USPTO") has issued U.S. Patent No. 8,178,518 covering, among other things, Testim 1% testosterone gel, marketed by Auxilium under license from FCB. The newly issued patent, which claims certain pharmaceutical compositions comprising testosterone, is expected to expire in April 2023. Auxilium has also submitted the patent for listing in the Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the U.S. Food and Drug Administration.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Kimbell Royalty closes $221.2M mineral rights acquisition
• Boeing names Ryan Shedd as new SVP and controller